Enhertu is a combination of a chemotherapy drug ... allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug ...

which can have serious side effects. Enhertu is already approved as a third-line therapy for HER2-positive metastatic breast cancer and a second-line therapy for HER2-positive metastatic gastric ...

They needed a stellar results with the drug however as Enhertu has been linked to an uncommon but potentially dangerous side effect – interstitial lung disease (ILD) – which may be linked to ...

Enhertu was also approved for HER2-positive ... Participants treated with Datroway also saw fewer severe side effects: the rate of severe adverse events was about 21% in the Datroway group and ...